Quadria Capital, a Singapore-headquartered private equity firm that invests in healthcare companies across India and Southeast Asia, has raised $595 million for its second fund.
Quadria Capital II is nearly double the size of its $304 million predecessor, which closed in 2015. Quadria said it set an initial target of $400 million. Fund I made nine mid-market investments in...
Increased climate change awareness on a corporate level is leading to more investment – either direct or through funds – in start-ups that offer mitigation solutions. Asia is a key geography
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.